Evaluation of clinical outcomes of anidulafungin for the treatment of candidemia in hospitalized critically ill patients with obesity: A multicenter, retrospective cohort study.

Autor:	Alsowaida YS; Department of Clinical Pharmacy, College of Pharmacy, University of Hail, Hail 55473, Saudi Arabia., Sulaiman KA; Pharmaceutical Care Services, King Abdulaziz Medical City, Riyadh, Saudi Arabia; College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; Saudi Critical Care Pharmacy Research (SCAPE) Platform, Riyadh, Saudi Arabia; Saudi Society for Multidisciplinary Research Development and Education (SCAPE Society), Riyadh, Saudi Arabia. Electronic address: alsulaimankh@hotmail.com., Mahrous AJ; Pharmacy Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia., Alharbi A; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; Pharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia; King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia., Bifari N; Pharmacy Practices Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia., Alshahrani WA; Pharmacist, Alshafi Medical Company, Riyadh, Saudi Arabia., Almangour TA; Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia., Damfu N; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia; Infection Prevention and Control Department, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Jeddah, Saudi Arabia; King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia., Banamah AA; College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia., Raya RRA; College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia., Sadawi RA; College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia., Alharbi A; Pharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia., Alsolami A; Department of Internal Medicine, College of Medicine, University of Ha'il, Ha'il, Saudi Arabia., Essa Y; Pharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia., Almagthali AG; Pharmaceutical Care Department, King Abdulaziz University, Jeddah, Saudi Arabia., Alhejaili SF; Pharmaceutical Care Services, King Abdulaziz University Hospital, Jeddah, Saudi Arabia; Pharmaceutical Care Services, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia., Qawwas WA; Department of Pharmaceutical Care Services, King Abdullah Medical City, Makkah, Saudi Arabia., Alharbi GS; Department of Pharmaceutical Care Services, King Abdullah Medical City, Makkah, Saudi Arabia., Alkeraidees AS; Pharmaceutical Care Services, King Abdulaziz Medical City, Ministry of National Guard Health Affairs (MNGHA), Riyadh, Saudi Arabia., Alshomrani A; Pharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia., Aljohani MA; Pharmaceutical Care Services, King Abdulaziz Medical City, Riyadh, Saudi Arabia; College of Pharmacy, King Saud Bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia; King Abdullah International Medical Research Center, Riyadh, Saudi Arabia., Aljuhani O; Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia.
Jazyk:	angličtina
Zdroj:	International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2024 Nov; Vol. 148, pp. 107234. Date of Electronic Publication: 2024 Sep 04.
DOI:	10.1016/j.ijid.2024.107234
Abstrakt:	Objectives: To evaluate the clinical outcomes of anidulafungin for candidemia treatment in critically ill patients with obesity. Methods: A multicenter, retrospective cohort study was conducted in Saudi Arabia for critically ill adults with candidemia who received anidulafungin. Patients with obesity have a body mass index ≥30 kg/m 2 . The primary outcome was the clinical cure rate. Results: A total of 146 patients were included, 64 of whom were obese. There were no statistically significant differences in the clinical cure rate (P = 0.63), microbiological cure rate (P = 0.27), or the median time for a clinical cure (P = 0.13) for patients with obesity compared to non-obese patients. The median time for a microbiological cure was longer in non-obese patients than in patients with obesity (P = 0.04). The median hospital length of stay and the median mechanical ventilation durations were numerically longer in patients with obesity. Conclusions: Clinical and microbiological cure rates and time for clinical cure were statistically similar for both groups. Considering the study's limitations (especially with a small sample size), it is uncertain if patients with obesity have similar effectiveness to non-obese patients. Future studies with larger sample sizes are warranted to evaluate if obesity negatively impacts anidulafungin's clinical outcomes for candidemia. Competing Interests: Declarations of competing interest The authors have no competing interests to declare. (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu